Gen-Probe prevails in Bayer viral diagnostics dispute
This article was originally published in Clinica
Executive Summary
An arbitrator has sided with San Diego nucleic acid testing (NAT) specialist Gen-Probe in its dispute with Bayer HealthCare over their viral diagnostics collaboration. Edward Wallin, of Judicial Arbitration & Mediation Service (JAMS), determined that Gen-Probe should have a joint right with Bayer to distribute qualitative TMA assays for the detection of hepatitis C and HIV-1.
You may also be interested in...
Vanda Comes Up Empty Handed As US Supreme Court Denies Hetlioz Appeal
Vanda looks likely to have to face up to unimpeded US generic competition to its core Hetlioz brand, after a further denial in its litigation against ANDA sponsors Teva and Apotex.
EU: Good News For IVDs And For Future Transparency Of Medtech Compliance
The IVD industry has long been awaiting a further extension of the deadlines for compliance with the IVD Regulation and for the launch date of the Eudamed database to be brought forward.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.